Invesco
ARCT icon

Invesco’s Arcturus Therapeutics ARCT Stock Holding History

Invesco’s Portfolio ARCT Stock Details ARCT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$700K Sell
104,188
-9,382
-8% -$74K ﹤0.01% 3099
2026
Q1 		$877K Buy
113,570
+10,454
+10% +$76.3K ﹤0.01% 2926
2025
Q4 		$632K Buy
103,116
+38,626
+60% +$417K ﹤0.01% 3117
2025
Q3 		$1.19M Buy
64,490
+19,629
+44% +$315K ﹤0.01% 2849
2025
Q2 		$584K Buy
44,861
+9,965
+29% +$118K ﹤0.01% 3093
2025
Q1 		$370K Buy
34,896
+15,836
+83% +$251K ﹤0.01% 3280
2024
Q4 		$323K Buy
19,060
+225
+1% +$4.24K ﹤0.01% 3390
2024
Q3 		$437K Buy
18,835
+156
+0.8% +$3.34K ﹤0.01% 3292
2024
Q2 		$455K Sell
18,679
-1,273
-6% -$38.6K ﹤0.01% 3309
2024
Q1 		$674K Buy
19,952
+6,696
+51% +$237K ﹤0.01% 3188
2023
Q4 		$418K Sell
13,256
-120,315
-90% -$2.86M ﹤0.01% 3311
2023
Q3 		$3.41M Buy
133,571
+122,953
+1,158% +$3.79M ﹤0.01% 2394
2023
Q2 		$305K Buy
10,618
+734
+7% +$20K ﹤0.01% 3492
2023
Q1 		$237K Sell
9,884
-15,462
-61% -$277K ﹤0.01% 3576
2022
Q4 		$430K Sell
25,346
-988
-4% -$17.2K ﹤0.01% 3346
2022
Q3 		$391K Buy
26,334
+177
+0.7% +$2.97K ﹤0.01% 3378
2022
Q2 		$412K Buy
26,157
+4,417
+20% +$86.7K ﹤0.01% 3431
2022
Q1 		$586K Buy
21,740
+13,473
+163% +$344K ﹤0.01% 3308
2021
Q4 		$306K Sell
8,267
-1,326
-14% -$54K ﹤0.01% 3604
2021
Q3 		$459K Buy
9,593
+839
+10% +$37.6K ﹤0.01% 3468
2021
Q2 		$295K Buy
8,754
+3,079
+54% +$104K ﹤0.01% 3635
2021
Q1 		$234K Buy
+5,675
New +$338K ﹤0.01% 3641
2020
Q4 		– Sell
-8,414
Closed -$362K – 3769
2020
Q3 		$362K Sell
8,414
-212,490
-96% -$10.5M ﹤0.01% 3248
2020
Q2 		$10.3M Buy
+220,904
New +$7.61M ﹤0.01% 1611

Other funds holding ARCT

Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $69.6B AUM 42.52% 1-Year Est. Return
AIM
ARK Investment Management St. Petersburg, Florida $15.4B AUM 50.29% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Sumitomo Mitsui Trust Group
Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $175B AUM 40.63% 1-Year Est. Return
NAMA
Nikko Asset Management Americas New York $7.75B AUM 33.73% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return

Invesco's ARCT Position: Q2 2026 in Review

Invesco reduced its Arcturus Therapeutics (ARCT) stake by 8.3% in Q2 2026, selling an estimated $74K and leaving 104,188 shares worth $700K. The position accounts for ﹤0.01% of the portfolio, ranked #3099.

Invesco first reported a position in ARCT in Q2 2020 and has held it in 24 quarters since. The position peaked at $10.3M in Q2 2020. 136 funds tracked by Wall St. Rank hold ARCT as of Q2 2026.

  • Invesco held 104,188 shares of Arcturus Therapeutics worth $700K as of Q2 2026.
  • Invesco sold 9,382 Arcturus Therapeutics shares in Q2 2026, an estimated $74K.
  • Arcturus Therapeutics made up ﹤0.01% of Invesco's portfolio in Q2 2026, its #3099 holding.
  • Invesco first reported a position in Arcturus Therapeutics in Q2 2020 and has held it in 24 quarters since.
  • Invesco's Arcturus Therapeutics position peaked at $10.3M in Q2 2020.
  • 136 funds tracked by Wall St. Rank held Arcturus Therapeutics as of Q2 2026.

Based on Invesco's 13F filing for Q2 2026, filed 14 Aug 2026.